Abstract：
:Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5 years. There is considerable heterogeneity in MCL, with some patients succumbing to their disease in less than a year and others surviving for more than 10 years. The biology of MCL is reasonably well understood, and targeted therapies based on this knowledge are in development. Clinical trials incorporating new agents into standard therapies are under way. The optimal frontline treatment strategy is not defined and is a source of controversy. Intensive therapies administered to younger patients appear to produce better-quality remission than standard treatments, and one randomized clinical trial demonstrates improved OS with an intensive approach. Additional randomized clinical trials defining standard approaches are needed.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Kahl BSdoi
10.1007/s11899-009-0028-zsubject
Has Abstractpub_date
2009-10-01 00:00:00pages
213-7issue
4eissn
1558-8211issn
1558-822Xjournal_volume
4pub_type
杂志文章,评审abstract：PURPOSE OF REVIEW:The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00561-w
更新日期：2020-02-01 00:00:00
abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0290-1
更新日期：2015-12-01 00:00:00
abstract：:Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0120-7
更新日期：2012-06-01 00:00:00
abstract：:Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-007-0037-8
更新日期：2007-10-01 00:00:00
abstract：PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0480-8
更新日期：2018-12-01 00:00:00
abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-011-0098-6
更新日期：2011-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has revolutionized the access and exchange of information in healthcare. The microblogging platform Twitter has been used by blood and marrow transplant physicians over the last several years with increasing enthusiasm. We review the adoption of Twitter in the transplant community and its...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0434-1
更新日期：2018-02-01 00:00:00
abstract：PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-019-00514-y
更新日期：2019-06-01 00:00:00
abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0449-7
更新日期：2018-06-01 00:00:00
abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...
journal_title：Current hematologic malignancy reports
pub_type： 已发布勘误
doi：10.1007/s11899-018-0488-0
更新日期：2019-02-01 00:00:00
abstract：:Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0227-0
更新日期：2014-12-01 00:00:00
abstract：:C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0193-y
更新日期：2014-03-01 00:00:00
abstract：:Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0379-9
更新日期：2017-06-01 00:00:00
abstract：PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00575-4
更新日期：2020-06-01 00:00:00
abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-019-00542-8
更新日期：2019-10-01 00:00:00
abstract：:In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0177-y
更新日期：2013-12-01 00:00:00
abstract：:Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0002-1
更新日期：2008-01-01 00:00:00
abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00593-2
更新日期：2020-08-01 00:00:00
abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-010-0043-0
更新日期：2010-04-01 00:00:00
abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00572-7
更新日期：2020-04-01 00:00:00
abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0023-4
更新日期：2009-07-01 00:00:00
abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0176-z
更新日期：2013-12-01 00:00:00
abstract：:Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-006-0021-8
更新日期：2006-06-01 00:00:00
abstract：:Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-996-0007-6
更新日期：2006-09-01 00:00:00
abstract：:The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0184-z
更新日期：2013-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0445-y
更新日期：2018-06-01 00:00:00
abstract：:Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0381-2
更新日期：2017-06-01 00:00:00
abstract：:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0386-x
更新日期：2017-06-01 00:00:00
abstract：:No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0013-6
更新日期：2009-04-01 00:00:00
abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00558-5
更新日期：2020-02-01 00:00:00
